{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:33:01Z","timestamp":1793773981901,"version":"4.6.1"},"reference-count":223,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["NANOTEC"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease marked by inflammation\nof synovium and generation of autoantibodies. Bone and cartilage are frequently damaged along\nwith weakening of tendons and ligaments resulting in disability. An effective RA treatment needs a\nmulti-disciplinary approach which relies upon pathophysiology that is still partially understood. In RA\npatients, inflammation was induced by pro-inflammatory cytokines including IL-1, IL-6 &amp; IL-10. The\nconventional dosage regimens for treating RA have drawbacks such as ineffectiveness, greater doses,\nfrequent dosing, relatively expensive and serious adverse effects. To formulate an effective treatment\nplan for RA, research teams have recently focused on producing several nanoformulations containing\nanti-inflammatory APIs with an aim to target the inflamed area. Nanomedicines have recently gained\npopularity in the treatment of RA. Interestingly, unbelievable improvements have been observed in current\nyears in diagnosis and management of RA utilizing nanotechnology. Various patents and clinical\ntrial data have been reported in relevance to RA treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872210518666230905155459","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:23:21Z","timestamp":1694406201000},"page":"56-75","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nano-based Therapeutics for Rheumatoid Arthritis: Recent Patents and Development"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2266-226X","authenticated-orcid":true,"given":"Manish","family":"Makhija","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith, Rajasthan, 304022, India"},{"name":"Department of Pharmaceutical Sciences,\nIndira Gandhi University, Meerpur, Rewari, 123401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-6609","authenticated-orcid":true,"given":"Deeksha","family":"Manchanda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith, Rajasthan, 304022, India"},{"name":"Department of Pharmaceutical Sciences,\nIndira Gandhi University, Meerpur, Rewari, 123401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-7449","authenticated-orcid":true,"given":"Manu","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith, Rajasthan, 304022, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrd.2016.21","volume":"15","author":"Chaudhari K.","year":"2016","unstructured":"Chaudhari K.; Rizvi S.; Syed B.A.; Rheumatoid arthritis: Current and future trends. Nat Rev Drug Discov  2016,15(5),305-306","journal-title":"Nat Rev Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.1039\/D1RA00328C","volume":"11","author":"Zheng M.","year":"2021","unstructured":"Zheng M.; Jia H.; Wang H.; Application of nanomaterials in the treatment of Rheumatoid arthritis. RSC Advances  2021,11(13),7129-7137","journal-title":"RSC Advances"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Guo Q.","year":"2018","unstructured":"Guo Q.; Wang Y.; Xu D.; Nossent J.; Pavlos N.J.; Xu J.; Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res  2018,6(1),15","journal-title":"Bone Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.jaci.2009.10.067","volume":"125","author":"Joseph A.","year":"2010","unstructured":"Joseph A.; Brasington R.; Kahl L.; Ranganathan P.; Cheng T.P.; Atkinson J.; Immunologic rheumatic disorders. J Allergy Clin Immunol  2010,125(2)(Suppl. 2),S204-S215","journal-title":"J Allergy Clin Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5114\/ceji.2017.70968","volume":"3","author":"Brzustewicz E.","year":"2017","unstructured":"Brzustewicz E.; Henc I.; Daca A.; Autoantibodies, C-reactive protein, erythrocyte sedimentation rate and serum cytokine profiling in monitoring of early treatment. Cent Eur J Immunol  2017,3(3),259-268","journal-title":"Cent Eur J Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"Lin Y.J.","year":"2020","unstructured":"Lin Y.J.; Anzaghe M.; Sch&#xFC;lke S.; Update on the pathomechanism, diagnosis, and treatment options for Rheumatoid arthritis. Cells  2020,9(4),880","journal-title":"Cells"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"Almutairi K.","year":"2021","unstructured":"Almutairi K.; Nossent J.; Preen D.; Keen H.; Inderjeeth C.; The global prevalence of Rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol Int  2021,41(5),863-877","journal-title":"Rheumatol Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.27425","volume":"62","author":"Myasoedova E.","year":"2010","unstructured":"Myasoedova E.; Crowson C.S.; Kremers H.M.; Therneau T.M.; Gabriel S.E.; Is the incidence of Rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum  2010,62(6),1576-1582","journal-title":"Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","volume":"35","author":"Ngo S.T.","year":"2014","unstructured":"Ngo S.T.; Steyn F.J.; McCombe P.A.; Gender differences in autoimmune disease. Front Neuroendocrinol  2014,35(3),347-369","journal-title":"Front Neuroendocrinol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"Crowson C.S.","year":"2011","unstructured":"Crowson C.S.; Matteson E.L.; Myasoedova E.; The lifetime risk of adult-onset Rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum  2011,63(3),633-639","journal-title":"Arthritis Rheum"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3899\/jrheum.200367","volume":"48","author":"Almutairi K.B.","year":"2021","unstructured":"Almutairi K.B.; Nossent J.C.; Preen D.B.; Keen H.I.; Inderjeeth C.A.; The prevalence of Rheumatoid arthritis: A systematic review of population-based studies. J Rheumatol  2021,48(5),669-676","journal-title":"J Rheumatol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2010.134684","volume":"69","author":"McInnes I.B.","year":"2010","unstructured":"McInnes I.B.; O\u2019Dell J.R.; State-of-the-art: Rheumatoid arthritis. Ann Rheum Dis  2010,69(11),1898-1906","journal-title":"Ann Rheum Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrrheum.2016.147","volume":"12","author":"Coutant F.","year":"2016","unstructured":"Coutant F.; Miossec P.; Altered dendritic cell functions in autoimmune diseases: Distinct and overlapping profiles. Nat Rev Rheumatol  2016,12(12),703-715","journal-title":"Nat Rev Rheumatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00296-017-3671-z","volume":"37","author":"Yu M.B.","year":"2017","unstructured":"Yu M.B.; Langridge W.H.R.; The function of myeloid dendritic cells in Rheumatoid arthritis. Rheumatol Int  2017,37(7),1043-1051","journal-title":"Rheumatol Int"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2017.02.032","volume":"252","author":"Yang M.","year":"2017","unstructured":"Yang M.; Feng X.; Ding J.; Chang F.; Chen X.; Nanotherapeutics relieve Rheumatoid arthritis. J Control Release  2017,252,108-124","journal-title":"J Control Release"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.biopha.2016.03.004","volume":"80","author":"Dolati S.","year":"2016","unstructured":"Dolati S.; Sadreddini S.; Rostamzadeh D.; Ahmadi M.; Jadidi-Niaragh F.; Yousefi M.; Utilization of nanoparticle technology in Rheumatoid arthritis treatment. Biomed Pharmacother  2016,80,30-41","journal-title":"Biomed Pharmacother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13105-012-0216-5","volume":"69","author":"Shrivastava A.K.","year":"2013","unstructured":"Shrivastava A.K.; Pandey A.; Inflammation and Rheumatoid arthritis. J Physiol Biochem  2013,69(2),335-347","journal-title":"J Physiol Biochem"},{"key":"ref=18","first-page":"359","volume":"3","author":"Hwang J.","year":"2008","unstructured":"Hwang J.; Rodgers K.; Oliver J.C.; Schluep T.; &#x3B1;-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for Rheumatoid arthritis therapy. Int J Nanomedicine  2008,3(3),359-371","journal-title":"Int J Nanomedicine"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"Aletaha D.","year":"2018","unstructured":"Aletaha D.; Smolen J.S.; Diagnosis and management of Rheumatoid arthritis: A review. JAMA  2018,320(13),1360-1372","journal-title":"JAMA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","volume":"455","author":"Mateen S.","year":"2016","unstructured":"Mateen S.; Zafar A.; Moin S.; Khan A.Q.; Zubair S.; Understanding the role of cytokines in the pathogenesis of Rheumatoid arthritis. Clin Chim Acta  2016,455,161-171","journal-title":"Clin Chim Acta"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cyto.2015.02.002","volume":"74","author":"Paulissen S.M.J.","year":"2015","unstructured":"Paulissen S.M.J.; van Hamburg J.P.; Dankers W.; Lubberts E.; The role and modulation of CCR6+ Th17 cell populations in Rheumatoid arthritis. Cytokine  2015,74(1),43-53","journal-title":"Cytokine"},{"key":"ref=22","first-page":"5407","volume":"10","author":"Roy K.","year":"2015","unstructured":"Roy K.; Kanwar R.K.; Kanwar J.R.; Molecular targets in arthritis and recent trends in nanotherapy. Int J Nanomedicine  2015,10,5407-5420","journal-title":"Int J Nanomedicine"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/wnan.157","volume":"3","author":"Pham C.T.N.","year":"2011","unstructured":"Pham C.T.N.; Nanotherapeutic approaches for the treatment of Rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2011,3(6),607-619","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jb\/mvt049","volume":"154","author":"Danks L.","year":"2013","unstructured":"Danks L.; Takayanagi H.; Immunology and bone. J Biochem  2013,154(1),29-39","journal-title":"J Biochem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3389\/fimmu.2019.02925","volume":"10","author":"Marahleh A.","year":"2019","unstructured":"Marahleh A.; Kitaura H.; Ohori F.; TNF-&#x3B1; directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front Immunol  2019,10,2925","journal-title":"Front Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"Lam J.","year":"2000","unstructured":"Lam J.; Takeshita S.; Barker J.E.; Kanagawa O.; Ross F.P.; Teitelbaum S.L.; TNF-&#x3B1; induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest  2000,106(12),1481-1488","journal-title":"J Clin Invest"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.191.2.275","volume":"191","author":"Kobayashi K.","year":"2000","unstructured":"Kobayashi K.; Takahashi N.; Jimi E.; Tumor necrosis factor &#x3B1; stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction. J Exp Med  2000,191(2),275-286","journal-title":"J Exp Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1074\/jbc.275.7.4858","volume":"275","author":"Azuma Y.","year":"2000","unstructured":"Azuma Y.; Kaji K.; Katogi R.; Takeshita S.; Kudo A.; Tumor necrosis factor-&#x3B1; induces differentiation of and bone resorption by osteoclasts. J Biol Chem  2000,275(7),4858-4864","journal-title":"J Biol Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha D.","year":"2010","unstructured":"Aletaha D.; Neogi T.; Silman A.J.; 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum  2010,62(9),2569-2581","journal-title":"Arthritis Rheum"},{"key":"ref=30","first-page":"200","volume":"70","author":"Scher J.U.","year":"2012","unstructured":"Scher J.U.; B-cell therapies for Rheumatoid arthritis. Bull NYU Hosp Jt Dis  2012,70(3),200-203","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"Nishimura K.","year":"2007","unstructured":"Nishimura K.; Sugiyama D.; Kogata Y.; Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and Rheumatoid factor for Rheumatoid arthritis. Ann Intern Med  2007,146(11),797-808","journal-title":"Ann Intern Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1155\/2013\/726598","volume":"35","author":"Ingegnoli F.","year":"2013","unstructured":"Ingegnoli F.; Castelli R.; Gualtierotti R.; Rheumatoid factors: Clinical applications. Dis Markers  2013,35(6),727-734","journal-title":"Dis Markers"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02686079","volume":"32","author":"Steiner G.","year":"2007","unstructured":"Steiner G.; Auto-antibodies and autoreactive T-cells in Rheumatoid arthritis. Clin Rev Allergy Immunol  2007,32(1),23-36","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.0105-2896.2009.00850.x","volume":"233","author":"Wegner N.","year":"2010","unstructured":"Wegner N.; Lundberg K.; Kinloch A.; Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of Rheumatoid arthritis. Immunol Rev  2010,233(1),34-54","journal-title":"Immunol Rev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24827","volume":"61","author":"Aggarwal R.","year":"2009","unstructured":"Aggarwal R.; Liao K.; Nair R.; Ringold S.; Costenbander K.H.; Anti-citrullinated peptide antibody assays and their role in the diagnosis of Rheumatoid arthritis. Arthritis Rheum  2009,61(11),1472-1483","journal-title":"Arthritis Rheum"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"Gerlag D.M.","year":"2019","unstructured":"Gerlag D.M.; Safy M.; Maijer K.I.; Effects of B-cell directed therapy on the preclinical stage of Rheumatoid arthritis: The PRAIRI study. Ann Rheum Dis  2019,78(2),179-185","journal-title":"Ann Rheum Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/ard.2003.014233","volume":"63","author":"Forslind K.","year":"2004","unstructured":"Forslind K.; Ahlm&#xE9;n M.; Eberhardt K.; Hafstr&#xF6;m I.; Svensson B.; Prediction of radiological outcome in early Rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis  2004,63(9),1090-1095","journal-title":"Ann Rheum Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/ard.2004.033571","volume":"64","author":"R&#xF6;nnelid J.","year":"2005","unstructured":"R&#xF6;nnelid J.; Wick M.C.; Lampa J.; Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early Rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis  2005,64(12),1744-1749","journal-title":"Ann Rheum Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard.2003.017574","volume":"63","author":"De Rycke L.","year":"2004","unstructured":"De Rycke L.; Peene I.; Hoffman I.E.A.; Rheumatoid factor and anticitrullinated protein antibodies in Rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis  2004,63(12),1587-1593","journal-title":"Ann Rheum Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jbspin.2019.01.005","volume":"86","author":"Coutant F.","year":"2019","unstructured":"Coutant F.; Pathogenic effects of anti-citrullinated protein antibodies in Rheumatoid arthritis \u2013 role for glycosylation. Joint Bone Spine  2019,86(5),562-567","journal-title":"Joint Bone Spine"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"Krishnamurthy A.","year":"2016","unstructured":"Krishnamurthy A.; Joshua V.; Haj Hensvold A.; Identification of a novel chemokine-dependent molecular mechanism underlying Rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis  2016,75(4),721-729","journal-title":"Ann Rheum Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","volume":"31","author":"Deane K.D.","year":"2017","unstructured":"Deane K.D.; Demoruelle M.K.; Kelmenson L.B.; Kuhn K.A.; Norris J.M.; Holers V.M.; Genetic and environmental risk factors for Rheumatoid arthritis. Best Pract Res Clin Rheumatol  2017,31(1),3-18","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"102797","DOI":"10.1016\/j.autrev.2021.102797","volume":"20","author":"Petrovsk&#xE1; N.","year":"2021","unstructured":"Petrovsk&#xE1; N.; Prajzlerov&#xE1; K.; Vencovsk&#xFD; J.; \u0160enolt L.; Filkov&#xE1; M.; The pre-clinical phase of Rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun Rev  2021,20(5),102797","journal-title":"Autoimmun Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","volume":"43","author":"MacGregor A.J.","year":"2000","unstructured":"MacGregor A.J.; Snieder H.; Rigby A.S.; Characterizing the quantitative genetic contribution to Rheumatoid arthritis using data from twins. Arthritis Rheum  2000,43(1),30-37","journal-title":"Arthritis Rheum"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.21739","volume":"54","author":"van der Helm-van Mil A.H.M.","year":"2006","unstructured":"van der Helm-van Mil A.H.M.; Verpoort K.N.; Breedveld F.C.; Huizinga T.W.J.; Toes R.E.M.; de Vries R.R.P.; The HLA\u2013DRB1 shared epitope alleles are primarily a risk factor for anti\u2013cyclic citrullinated peptide antibodies and are not an independent risk factor for development of Rheumatoid arthritis. Arthritis Rheum  2006,54(4),1117-1121","journal-title":"Arthritis Rheum"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/art.24135","volume":"60","author":"Ding B.","year":"2009","unstructured":"Ding B.; Padyukov L.; Lundstr&#xF6;m E.; Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative Rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum  2009,60(1),30-38","journal-title":"Arthritis Rheum"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar2214","volume":"9","author":"Kokkonen H.","year":"2007","unstructured":"Kokkonen H.; Johansson M.; Innala L.; Jidell E.; Rantap&#xE4;-Dahlqvist S.; The PTPN22 1858C\/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early Rheumatoid arthritis in northern Sweden. Arthritis Res Ther  2007,9(3),R56","journal-title":"Arthritis Res Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1086\/516736","volume":"80","author":"K&#xE4;llberg H.","year":"2007","unstructured":"K&#xE4;llberg H.; Padyukov L.; Plenge R.M.; Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of Rheumatoid arthritis. Am J Hum Genet  2007,80(5),867-875","journal-title":"Am J Hum Genet"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11033-013-2864-0","volume":"41","author":"Zhang X.","year":"2014","unstructured":"Zhang X.; Li W.; Zhang X.; Association between polymorphism in TRAF1\/C5 gene and risk of Rheumatoid arthritis: A meta-analysis. Mol Biol Rep  2014,41(1),317-324","journal-title":"Mol Biol Rep"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/art.22704","volume":"56","author":"Sigurdsson S.","year":"2007","unstructured":"Sigurdsson S.; Padyukov L.; Kurreeman F.A.S.; Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with Rheumatoid arthritis. Arthritis Rheum  2007,56(7),2202-2210","journal-title":"Arthritis Rheum"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"Smolen J.S.","year":"2016","unstructured":"Smolen J.S.; Aletaha D.; McInnes I.B.; Rheumatoid arthritis. Lancet  2016,388(10055),2023-2038","journal-title":"Lancet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.rdc.2017.04.003","volume":"43","author":"van Drongelen V.","year":"2017","unstructured":"van Drongelen V.; Holoshitz J.; Human leukocyte antigen\u2013disease associations in Rheumatoid arthritis. Rheum Dis Clin North Am  2017,43(3),363-376","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.2015.3435","volume":"313","author":"Viatte S.","year":"2015","unstructured":"Viatte S.; Plant D.; Han B.; Association of HLA-DRB1 haplotypes with Rheumatoid arthritis severity, mortality, and treatment re-sponse. JAMA  2015,313(16),1645-1656","journal-title":"JAMA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1086\/422827","volume":"75","author":"Begovich A.B.","year":"2004","unstructured":"Begovich A.B.; Carlton V.E.H.; Honigberg L.A.; A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with Rheumatoid arthritis. Am J Hum Genet  2004,75(2),330-337","journal-title":"Am J Hum Genet"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/sj.gene.6364159","volume":"6","author":"Lee A.T.","year":"2005","unstructured":"Lee A.T.; Li W.; Liew A.; The PTPN22 R620W polymorphism associates with RF positive Rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun  2005,6(2),129-133","journal-title":"Genes Immun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1568-9972(02)00064-2","volume":"1","author":"Cutolo M.","year":"2002","unstructured":"Cutolo M.; Villaggio B.; Craviotto C.; Pizzorni C.; Seriolo B.; Sulli A.; Sex hormones and Rheumatoid arthritis. Autoimmun Rev  2002,1(5),284-289","journal-title":"Autoimmun Rev"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/ard.2009.111179","volume":"69","author":"Salliot C.","year":"2010","unstructured":"Salliot C.; Bombardier C.; Saraux A.; Combe B.; Dougados M.; Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and\/or *04 alleles by protecting against the production of anti-CCP: Results from the ESPOIR cohort. Ann Rheum Dis  2010,69(9),1683-1686","journal-title":"Ann Rheum Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"A288","DOI":"10.1016\/j.autrev.2009.11.019","volume":"9","author":"Tob&#xF3;n G.J.","year":"2010","unstructured":"Tob&#xF3;n G.J.; Youinou P.; Saraux A.; The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. Autoimmun Rev  2010,9(5),A288-A292","journal-title":"Autoimmun Rev"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pop.2018.02.010","volume":"45","author":"Littlejohn E.A.","year":"2018","unstructured":"Littlejohn E.A.; Monrad S.U.; Early diagnosis and treatment of Rheumatoid arthritis. Prim Care  2018,45(2),237-255","journal-title":"Prim Care"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1128\/IAI.67.7.3248-3256.1999","volume":"67","author":"McGraw W.T.","year":"1999","unstructured":"McGraw W.T.; Potempa J.; Farley D.; Travis J.; Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun  1999,67(7),3248-3256","journal-title":"Infect Immun"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20160792","volume":"213","author":"Tan E.M.","year":"2016","unstructured":"Tan E.M.; Smolen J.S.; Historical observations contributing insights on etiopathogenesis of Rheumatoid arthritis and role of Rheumatoid factor. J Exp Med  2016,213(10),1937-1950","journal-title":"J Exp Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"Harley J.B.","year":"2018","unstructured":"Harley J.B.; Chen X.; Pujato M.; Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet  2018,50(5),699-707","journal-title":"Nat Genet"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1286-4579(00)01303-4","volume":"2","author":"Wilson C.","year":"2000","unstructured":"Wilson C.; Tiwana H.; Ebringer A.; Molecular mimicry between HLA-DR alleles associated with Rheumatoid arthritis and Proteus mirabilis as the aetiological basis for autoimmunity. Microbes Infect  2000,2(12),1489-1496","journal-title":"Microbes Infect"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1128\/IAI.67.6.2769-2775.1999","volume":"67","author":"Tiwana H.","year":"1999","unstructured":"Tiwana H.; Wilson C.; Alvarez A.; Abuknesha R.; Bansal S.; Ebringer A.; Cross-reactivity between the Rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun  1999,67(6),2769-2775","journal-title":"Infect Immun"},{"key":"ref=65","first-page":"174","volume":"4","author":"Li S.","year":"2013","unstructured":"Li S.; Yu Y.; Yue Y.; Zhang Z.; Su K.; Microbial infection and Rheumatoid arthritis. J Clin Cell Immunol  2013,4(6),174","journal-title":"J Clin Cell Immunol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0010-7824(87)90082-5","volume":"35","author":"Vessey M.P.","year":"1987","unstructured":"Vessey M.P.; Villard-Mackintosh L.; Yeates D.; Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception  1987,35(5),457-464","journal-title":"Contraception"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s10067-014-2631-1","volume":"33","author":"Lee Y.H.","year":"2014","unstructured":"Lee Y.H.; Bae S.C.; Song G.G.; Coffee or tea consumption and the risk of Rheumatoid arthritis: A meta-analysis. Clin Rheumatol  2014,33(11),1575-1583","journal-title":"Clin Rheumatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/EDE.0b013e3181b5f0ce","volume":"20","author":"Rosell M.","year":"2009","unstructured":"Rosell M.; Wesley A.M.; Rydin K.; Klareskog L.; Alfredsson L.; Dietary fish and fish oil and the risk of Rheumatoid arthritis. Epidemiology  2009,20(6),896-901","journal-title":"Epidemiology"},{"key":"ref=69","first-page":"1310","volume":"31","author":"Pattison D.J.","year":"2004","unstructured":"Pattison D.J.; Harrison R.A.; Symmons D.P.; The role of diet in susceptibility to Rheumatoid arthritis: A systematic review. J Rheumatol  2004,31(7),1310-1319","journal-title":"J Rheumatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/ar2123","volume":"9","author":"Benito-Garcia E.","year":"2007","unstructured":"Benito-Garcia E.; Feskanich D.; Hu F.B.; Mandl L.A.; Karlson E.W.; Protein, iron, and meat consumption and risk for Rheumatoid arthritis: A prospective cohort study. Arthritis Res Ther  2007,9(1),R16","journal-title":"Arthritis Res Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.shaw.2020.02.001","volume":"11","author":"Mehri F.","year":"2020","unstructured":"Mehri F.; Jenabi E.; Bashirian S.; Shahna F.G.; Khazaei S.; The association between occupational exposure to silica and risk of developing Rheumatoid arthritis: A meta-analysis. Saf Health Work  2020,11(2),136-142","journal-title":"Saf Health Work"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.radcr.2018.03.004","volume":"13","author":"Alaya Z.","year":"2018","unstructured":"Alaya Z.; Braham M.; Aissa S.; Kalboussi H.; Bouajina E.; A case of Caplan syndrome in a recently diagnosed patient with silicosis: A case report. Radiol Case Rep  2018,13(3),663-666","journal-title":"Radiol Case Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/bmj.326.7394.859","volume":"326","author":"Samanta J.","year":"2003","unstructured":"Samanta J.; Kendall J.; Samanta A.; 10-minute consultation: Polyarthralgia. BMJ  2003,326(7394),859","journal-title":"BMJ"},{"key":"ref=74","first-page":"242","volume":"57","year":"2018","unstructured":"2018 Chinese guideline for the diagnosis and treatment of Rheumatoid arthritis. Zhonghua Nei Ke Za Zhi  2018,57(4),242-251","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4102\/sajr.v22i1.1316","volume":"22","author":"Kgoebane K.","year":"2018","unstructured":"Kgoebane K.; Ally M.M.T.M.; Duim-Beytell M.C.; Suleman F.E.; The role of imaging in Rheumatoid arthritis. SA J Radiol  2018,22(1),1316","journal-title":"SA J Radiol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1038\/s41598-019-38548-0","volume":"9","author":"Bhatnagar S.","year":"2019","unstructured":"Bhatnagar S.; Khera E.; Liao J.; Oral and subcutaneous administration of a near-infrared fluorescent molecular imaging agent detects inflammation in a mouse model of Rheumatoid arthritis. Sci Rep  2019,9(1),4661","journal-title":"Sci Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.mpmed.2017.12.004","volume":"46","author":"Cheung K.K.","year":"2018","unstructured":"Cheung K.K.; Hall-Craggs M.A.; Update on imaging in rheumatology \u2013 recent advances. Medicine (Abingdon)  2018,46(3),170-174","journal-title":"Medicine (Abingdon)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12016-009-8166-6","volume":"39","author":"Trenkmann M.","year":"2010","unstructured":"Trenkmann M.; Brock M.; Ospelt C.; Gay S.; Epigenetics in Rheumatoid arthritis. Clin Rev Allergy Immunol  2010,39(1),10-19","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/art.23386","volume":"58","author":"Stanczyk J.","year":"2008","unstructured":"Stanczyk J.; Pedrioli D.M.L.; Brentano F.; Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in Rheumatoid arthritis. Arthritis Rheum  2008,58(4),1001-1009","journal-title":"Arthritis Rheum"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/art.23429","volume":"58","author":"Nakasa T.","year":"2008","unstructured":"Nakasa T.; Miyaki S.; Okubo A.; Expression of microRNA-146 in Rheumatoid arthritis synovial tissue. Arthritis Rheum  2008,58(5),1284-1292","journal-title":"Arthritis Rheum"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13075-017-1492-9","volume":"19","author":"Ouboussad L.","year":"2017","unstructured":"Ouboussad L.; Hunt L.; Hensor E.M.A.; Profiling microRNAs in individuals at risk of progression to Rheumatoid arthritis. Arthritis Res Ther  2017,19(1),288","journal-title":"Arthritis Res Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s12276-022-00751-x","volume":"54","author":"Wu L.F.","year":"2022","unstructured":"Wu L.F.; Zhang Q.; Mo X.B.; Identification of novel Rheumatoid arthritis-associated MiRNA-204-5p from plasma exosomes. Exp Mol Med  2022,54(3),334-345","journal-title":"Exp Mol Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mcna.2020.10.006","volume":"105","author":"Cush J.J.","year":"2021","unstructured":"Cush J.J.; Rheumatoid arthritis. Med Clin North Am  2021,105(2),355-365","journal-title":"Med Clin North Am"},{"key":"ref=84","first-page":"159","volume":"106","author":"Egerer K.","year":"2009","unstructured":"Egerer K.; Feist E.; Burmester G.R.; The serological diagnosis of Rheumatoid arthritis: Antibodies to citrullinated antigens. Dtsch Arztebl Int  2009,106(10),159-163","journal-title":"Dtsch Arztebl Int"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"685312","DOI":"10.3389\/fimmu.2021.685312","volume":"12","author":"R&#xF6;nnelid J.","year":"2021","unstructured":"R&#xF6;nnelid J.; Turesson C.; Kastbom A.; Autoantibodies in Rheumatoid arthritis \u2013 Laboratory and clinical perspectives. Front Immunol  2021,12,685312","journal-title":"Front Immunol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"Smolen J.S.","year":"2016","unstructured":"Smolen J.S.; Breedveld F.C.; Burmester G.R.; Treating Rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis  2016,75(1),3-15","journal-title":"Ann Rheum Dis"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/jcm8070938","volume":"8","author":"K&#xF6;hler B.M.","year":"2019","unstructured":"K&#xF6;hler B.M.; G&#xFC;nther J.; Kaudewitz D.; Lorenz H.M.; Current therapeutic options in the treatment of Rheumatoid arthritis. J Clin Med  2019,8(7),938","journal-title":"J Clin Med"},{"key":"ref=88","author":"Staheli L.T.","year":"1998","unstructured":"Staheli L.T.; Hall J.G.; Jaffe K.M.; Paholke D.O.;  Arthrogryposis: A text atlas  1998","journal-title":"Arthrogryposis: A text atlas"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"Fraenkel L.","year":"2021","unstructured":"Fraenkel L.; Bathon J.M.; England B.R.; 2021 American College of Rheumatology guideline for the treatment of Rheumatoid arthritis. Arthritis Rheumatol  2021,73(7),1108-1123","journal-title":"Arthritis Rheumatol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"Smolen J.S.","year":"2020","unstructured":"Smolen J.S.; Landew&#xE9; R.B.M.; Bijlsma J.W.J.; EULAR recommendations for the management of Rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis  2020,79(6),685-699","journal-title":"Ann Rheum Dis"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3121\/cmr.2007.698","volume":"5","author":"Ong C.K.S.","year":"2007","unstructured":"Ong C.K.S.; Lirk P.; Tan C.H.; Seymour R.A.; An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res  2007,5(1),19-34","journal-title":"Clin Med Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar4174","volume":"15","author":"Crofford L.J.","year":"2013","unstructured":"Crofford L.J.; Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther  2013,15(S3)(Suppl. 3),S2","journal-title":"Arthritis Res Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"van Everdingen A.A.","year":"2002","unstructured":"van Everdingen A.A.; Jacobs J.W.G.; Siewertsz van Reesema D.R.; Bijlsma J.W.J.; Low-dose prednisone therapy for patients with early active Rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med  2002,136(1),1-12","journal-title":"Ann Intern Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","volume":"27","author":"Bullock J.","year":"2018","unstructured":"Bullock J.; Rizvi S.A.A.; Saleh A.M.; Rheumatoid arthritis: A brief overview of the treatment. Med Princ Pract  2018,27(6),501-507","journal-title":"Med Princ Pract"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jpain.2015.05.002","volume":"16","author":"Nahin R.L.","year":"2015","unstructured":"Nahin R.L.; Estimates of pain prevalence and severity in adults: United States, 2012. J Pain  2015,16(8),769-780","journal-title":"J Pain"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3899\/jrheum.120341","volume":"90","author":"Whittle S.L.","year":"2012","unstructured":"Whittle S.L.; Richards B.L.; van der HEIJDE DM, Buchbinder R. The efficacy and safety of opioids in inflammatory arthritis: A Cochrane systematic review. J Rheumatol Suppl  2012,90,40-46","journal-title":"J Rheumatol Suppl"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10067-016-3239-4","volume":"35","author":"Zamora-Legoff J.A.","year":"2016","unstructured":"Zamora-Legoff J.A.; Achenbach S.J.; Crowson C.S.; Krause M.L.; Davis J.M.; Matteson E.L.; Opioid use in patients with Rheumatoid arthritis 2005\u20132014: A population-based comparative study. Clin Rheumatol  2016,35(5),1137-1144","journal-title":"Clin Rheumatol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10067-016-3528-y","volume":"36","author":"Monti S.","year":"2017","unstructured":"Monti S.; Klersy C.; Gorla R.; Factors influencing the choice of first- and second-line biologic therapy for the treatment of Rheumatoid arthritis: Real-life data from the Italian LORHEN Registry. Clin Rheumatol  2017,36(4),753-761","journal-title":"Clin Rheumatol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13075-020-02391-w","volume":"22","author":"Bywall K.S.","year":"2020","unstructured":"Bywall K.S.; Kihlbom U.; Hansson M.; Patient preferences on Rheumatoid arthritis second-line treatment: A discrete choice experiment of Swedish patients. Arthritis Res Ther  2020,22(1),288","journal-title":"Arthritis Res Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1872210514666200204124130","volume":"14","author":"Pandey K.","year":"2020","unstructured":"Pandey K.; Nimisha. An overview on promising nanotechnological approaches for the treatment of psoriasis. Recent Pat Nanotechnol  2020,14(2),102-118","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"Nam J.L.","year":"2017","unstructured":"Nam J.L.; Takase-Minegishi K.; Ramiro S.; Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of Rheumatoid arthritis. Ann Rheum Dis  2017,76(6),1113-1136","journal-title":"Ann Rheum Dis"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","volume":"44","author":"Van Ede A.E.","year":"2001","unstructured":"Van Ede A.E.; Laan R.F.J.M.; Rood M.J.; Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in Rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum  2001,44(7),1515-1524","journal-title":"Arthritis Rheum"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12891-016-1213-6","volume":"17","author":"O\u2019Connor A.","year":"2016","unstructured":"O\u2019Connor A.; Thorne C.; Kang H.; Tin D.; Pope J.E.; The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: An observational study. BMC Musculoskelet Disord  2016,17(1),364","journal-title":"BMC Musculoskelet Disord"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","volume":"23","author":"Behrens F.","year":"2011","unstructured":"Behrens F.; Koehm M.; Burkhardt H.; Update 2011: Leflunomide in Rheumatoid arthritis \u2013 strengths and weaknesses. Curr Opin Rheumatol  2011,23(3),282-287","journal-title":"Curr Opin Rheumatol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","volume":"41","author":"Rozman B.","year":"2002","unstructured":"Rozman B.; Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet  2002,41(6),421-430","journal-title":"Clin Pharmacokinet"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2146\/ajhp050514","volume":"63","author":"Gaffo A.","year":"2006","unstructured":"Gaffo A.; Saag K.G.; Curtis J.R.; Treatment of Rheumatoid arthritis. Am J Health Syst Pharm  2006,63(24),2451-2465","journal-title":"Am J Health Syst Pharm"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.reumae.2017.07.011","volume":"15","author":"Alfaro-Lara R.","year":"2019","unstructured":"Alfaro-Lara R.; Espinosa-Ortega H.F.; Arce-Salinas C.A.; Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of Rheumatoid arthritis. Reumatolog&#xED;a\nCl&#xED;nica (English Edition)  2019,15(3),133-139","journal-title":"Reumatolog&#xED;a\nCl&#xED;nica (English Edition)"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/art.11015","volume":"48","author":"Kalden J.R.","year":"2003","unstructured":"Kalden J.R.; Schattenkirchner M.; S&#xF6;rensen H.; The efficacy and safety of leflunomide in patients with active Rheumatoid arthritis: A five-year followup study. Arthritis Rheum  2003,48(6),1513-1520","journal-title":"Arthritis Rheum"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","volume":"68","author":"da Silva J.C.","year":"2013","unstructured":"da Silva J.C.; Mariz H.A.; da Rocha J&#xFA;nior L.F.; Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and Rheumatoid arthritis patients. Clinics (S&#xE3;o Paulo)  2013,68(6),766-771","journal-title":"Clinics (S&#xE3;o Paulo)"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/0886022X.2017.1399908","volume":"39","author":"Niknahad H.","year":"2017","unstructured":"Niknahad H.; Heidari R.; Mohammadzadeh R.; Sulfasalazine induces mitochondrial dysfunction and renal injury. Ren Fail  2017,39(1),745-753","journal-title":"Ren Fail"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1006\/exmp.2002.2460","volume":"73","author":"Volin M.V.","year":"2002","unstructured":"Volin M.V.; Campbell P.L.; Connors M.A.; Woodruff D.C.; Koch A.E.; The effect of sulfasalazine on Rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol  2002,73(2),84-92","journal-title":"Exp Mol Pathol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1093\/ndt\/gfp277","volume":"24","author":"Augusto J.F.","year":"2009","unstructured":"Augusto J.F.; Sayegh J.; Simon A.; A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant  2009,24(9),2940-2942","journal-title":"Nephrol Dial Transplant"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"A32","DOI":"10.1016\/j.cgh.2011.09.027","volume":"10","author":"DeMichele J.","year":"2012","unstructured":"DeMichele J.; Rezaizadeh H.; Goldstein J.I.; Sulfasalazine crystalluria-induced anuric renal failure. Clin Gastroenterol Hepatol  2012,10(2),A32","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/acr.23255","volume":"69","author":"Peper S.M.","year":"2017","unstructured":"Peper S.M.; Lew R.; Mikuls T.; Rheumatoid arthritis treatment after methotrexate: The durability of triple therapy versus etanercept. Arthritis Care Res  2017,69(10),1467-1472","journal-title":"Arthritis Care Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.autrev.2021.102758","volume":"20","author":"Boutet M.A.","year":"2021","unstructured":"Boutet M.A.; Courties G.; Nerviani A.; Novel insights into macrophage diversity in Rheumatoid arthritis synovium. Autoimmun Rev  2021,20(3),102758","journal-title":"Autoimmun Rev"},{"key":"ref=116","first-page":"53","volume":"143","author":"Miller D.R.","year":"1999","unstructured":"Miller D.R.; Treatment options for Rheumatoid arthritis. Drug Top  1999,143,53-62","journal-title":"Drug Top"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrd1343","volume":"3","author":"Arkin M.R.","year":"2004","unstructured":"Arkin M.R.; Wells J.A.; Small-molecule inhibitors of protein\u2013protein interactions: Progressing towards the dream. Nat Rev Drug Discov  2004,3(4),301-317","journal-title":"Nat Rev Drug Discov"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"Dhillon S.","year":"2017","unstructured":"Dhillon S.; Tofacitinib: A review in Rheumatoid arthritis. Drugs  2017,77(18),1987-2001","journal-title":"Drugs"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40264-016-0430-0","volume":"39","author":"Yamaoka K.","year":"2016","unstructured":"Yamaoka K.; Benefit and risk of tofacitinib in the treatment of Rheumatoid arthritis: A focus on herpes zoster. Drug Saf  2016,39(9),823-840","journal-title":"Drug Saf"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph12010037","volume":"12","author":"Mayence A.","year":"2019","unstructured":"Mayence A.; Vanden E.J.; Baricitinib A.; 2018 novel FDA-approved small molecule inhibiting janus kinases. Pharmaceuticals  2019,12(1),37","journal-title":"Pharmaceuticals"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10067-018-4199-7","volume":"37","author":"Kunwar S.","year":"2018","unstructured":"Kunwar S.; Collins C.E.; Constantinescu F.; Baricitinib, a Janus kinase inhibitor, in the treatment of Rheumatoid arthritis: A systematic litera-ture review and meta-analysis of randomized controlled trials. Clin Rheumatol  2018,37(10),2611-2620","journal-title":"Clin Rheumatol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"e17088","DOI":"10.1097\/MD.0000000000017088","volume":"98","author":"Salaffi F.","year":"2019","unstructured":"Salaffi F.; Carotti M.; Di Carlo M.; Tardella M.; Giovagnoni A.; High-resolution computed tomography of the lung in patients with Rheumatoid arthritis. Medicine (Baltimore)  2019,98(38),e17088","journal-title":"Medicine (Baltimore)"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"McInnes I.B.","year":"2019","unstructured":"McInnes I.B.; Byers N.L.; Higgs R.E.; Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther  2019,21(1),183","journal-title":"Arthritis Res Ther"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.phrs.2019.104392","volume":"147","author":"Bechman K.","year":"2019","unstructured":"Bechman K.; Yates M.; Galloway J.B.; The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacol Res  2019,147,104392","journal-title":"Pharmacol Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/1060028019839650","volume":"53","author":"Mogul A.","year":"2019","unstructured":"Mogul A.; Corsi K.; McAuliffe L.; Baricitinib: The second FDA-approved JAK inhibitor for the treatment of Rheumatoid arthritis. Ann Pharmacother  2019,53(9),947-953","journal-title":"Ann Pharmacother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","volume":"18","author":"Qiu C.","year":"2019","unstructured":"Qiu C.; Zhao X.; She L.; Baricitinib induces LDL-C and HDL-C increases in Rheumatoid arthritis: A meta-analysis of randomized controlled trials. Lipids Health Dis  2019,18(1),54","journal-title":"Lipids Health Dis"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"You H.","year":"2020","unstructured":"You H.; Xu D.; Zhao J.; JAK inhibitors: Prospects in connective tissue diseases. Clin Rev Allergy Immunol  2020,59(3),334-351","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13018-021-02603-2","volume":"16","author":"Hu C.J.","year":"2021","unstructured":"Hu C.J.; Zhang L.; Zhou S.; Effectiveness of iguratimod as monotherapy or combined therapy in patients with Rheumatoid arthritis: A systematic review and meta-analysis of RCTs. J Orthop Surg Res  2021,16(1),457","journal-title":"J Orthop Surg Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","volume":"64","author":"Xie Z.","year":"2021","unstructured":"Xie Z.; Yang X.; Duan Y.; Han J.; Liao C.; Small-molecule kinase inhibitors for the treatment of nononcologic diseases. J Med Chem  2021,64(3),1283-1345","journal-title":"J Med Chem"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","volume":"4","author":"Rein P.","year":"2017","unstructured":"Rein P.; Mueller R.B.; Treatment with biologicals in Rheumatoid arthritis: An overview. Rheumatol Ther  2017,4(2),247-261","journal-title":"Rheumatol Ther"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nri3193","volume":"12","author":"deLuca L.S.","year":"2012","unstructured":"deLuca L.S.; Gommerman J.L.; Fine-tuning of dendritic cell biology by the TNF superfamily. Nat Rev Immunol  2012,12(5),339-351","journal-title":"Nat Rev Immunol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"572475","DOI":"10.3389\/fimmu.2020.572475","volume":"11","author":"Mahmood Z.","year":"2020","unstructured":"Mahmood Z.; Schmalzing M.; D&#xF6;rner T.; Tony H.P.; Muhammad K.; Therapeutic cytokine inhibition modulates activation and homing receptors of peripheral memory b cell subsets in Rheumatoid arthritis patients. Front Immunol  2020,11,572475","journal-title":"Front Immunol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinthera.2018.04.016","volume":"40","author":"Pala O.","year":"2018","unstructured":"Pala O.; Diaz A.; Blomberg B.B.; Frasca D.; B lymphocytes in Rheumatoid arthritis and the effects of anti\u2013TNF-&#x3B1; agents on B lymphocytes: A review of the literature. Clin Ther  2018,40(6),1034-1045","journal-title":"Clin Ther"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"Charles P.","year":"1999","unstructured":"Charles P.; Elliott M.J.; Davis D.; Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-&#x3B1; therapy in Rheumatoid arthritis. J Immunol  1999,163(3),1521-1528","journal-title":"J Immunol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.3748\/wjg.v21.i40.11282","volume":"21","author":"G&#xF3;mez-G&#xF3;mez G.J.","year":"2015","unstructured":"G&#xF3;mez-G&#xF3;mez G.J.; Masedo &#xC1;.; Yela C.; Mart&#xED;nez-Montiel M.P.; Cas&#xED;s B.; Current stage in inflammatory bowel disease: What is next? World J Gastroenterol  2015,21(40),11282-11303","journal-title":"World J Gastroenterol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","volume":"29","author":"Ogata A.","year":"2019","unstructured":"Ogata A.; Kato Y.; Higa S.; Yoshizaki K.; IL-6 inhibitor for the treatment of Rheumatoid arthritis: A comprehensive review. Mod Rheumatol  2019,29(2),258-267","journal-title":"Mod Rheumatol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","volume":"11","author":"Raimondo M.G.","year":"2017","unstructured":"Raimondo M.G.; Biggioggero M.; Crotti C.; Becciolini A.; Favalli E.G.; Profile of sarilumab and its potential in the treatment of Rheumatoid arthritis. Drug Des Devel Ther  2017,11,1593-1603","journal-title":"Drug Des Devel Ther"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13075-018-1527-x","volume":"20","author":"Bozec A.","year":"2018","unstructured":"Bozec A.; Luo Y.; Engdahl C.; Figueiredo C.; Bang H.; Schett G.; Abatacept blocks anti-citrullinated protein antibody and Rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner. Arthritis Res Ther  2018,20(1),24","journal-title":"Arthritis Res Ther"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3899\/jrheum.091066","volume":"37","author":"Maxwell L.J.","year":"2010","unstructured":"Maxwell L.J.; Singh J.A.; Abatacept for Rheumatoid arthritis: A Cochrane systematic review. J Rheumatol  2010,37(2),234-245","journal-title":"J Rheumatol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10354-019-00710-8","volume":"170","author":"Peichl P.","year":"2020","unstructured":"Peichl P.; Alten R.; Galeazzi M.; Abatacept retention and clinical outcomes in Austrian patients with Rheumatoid arthritis: Real-world data from the 2-year ACTION study. Wien Med Wochenschr  2020,170(5-6),132-140","journal-title":"Wien Med Wochenschr"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"Blair H.A.","year":"2017","unstructured":"Blair H.A.; Deeks E.D.; Abatacept: A review in Rheumatoid arthritis. Drugs  2017,77(11),1221-1233","journal-title":"Drugs"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00296-016-3444-0","volume":"36","author":"Mysler E.","year":"2016","unstructured":"Mysler E.; Pineda C.; Horiuchi T.; Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int  2016,36(5),613-625","journal-title":"Rheumatol Int"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"Yoo D.H.","year":"2013","unstructured":"Yoo D.H.; Hrycaj P.; Miranda P.; A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active Rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis  2013,72(10),1613-1620","journal-title":"Ann Rheum Dis"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"Yoo D.H.","year":"2016","unstructured":"Yoo D.H.; Racewicz A.; Brzezicki J.; A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active Rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther  2016,18(1),82","journal-title":"Arthritis Res Ther"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.addr.2012.03.006","volume":"64","author":"Yuan F.","year":"2012","unstructured":"Yuan F.; Quan L.; Cui L.; Goldring S.R.; Wang D.; Development of macromolecular prodrug for Rheumatoid arthritis. Adv Drug Deliv Rev  2012,64(12),1205-1219","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.39537","volume":"68","author":"Movahedi M.","year":"2016","unstructured":"Movahedi M.; Beauchamp M.E.; Abrahamowicz M.; Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with Rheumatoid arthritis. Arthritis Rheumatol  2016,68(5),1089-1098","journal-title":"Arthritis Rheumatol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2217\/nnm-2018-0501","volume":"14","author":"Meka R.R.","year":"2019","unstructured":"Meka R.R.; Venkatesha S.H.; Acharya B.; Moudgil K.D.; Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy. Nanomedicine (Lond)  2019,14(11),1455-1469","journal-title":"Nanomedicine (Lond)"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s12272-011-1109-9","volume":"34","author":"Mitragotri S.","year":"2011","unstructured":"Mitragotri S.; Yoo J.W.; Designing micro- and nano-particles for treating Rheumatoid arthritis. Arch Pharm Res  2011,34(11),1887-1897","journal-title":"Arch Pharm Res"},{"key":"ref=149","first-page":"1","volume":"20","author":"Bahadar H.","year":"2016","unstructured":"Bahadar H.; Maqbool F.; Niaz K.; Abdollahi M.; Toxicity of nanoparticles and an overview of current experimental models. Iran Biomed J  2016,20(1),1-11","journal-title":"Iran Biomed J"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1872210514666200909154409","volume":"15","author":"Purohit D.","year":"2021","unstructured":"Purohit D.; Manchanda D.; Makhija M.; An overview of the recent developments and patents in the field of pharmaceutical nanotechnology. Recent Pat Nanotechnol  2021,15(1),15-34","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1007\/s12274-018-2071-3","volume":"11","author":"Oliveira I.M.","year":"2018","unstructured":"Oliveira I.M.; Gon&#xE7;alves C.; Reis R.L.; Oliveira J.M.; Engineering nanoparticles for targeting Rheumatoid arthritis: Past, present, and future trends. Nano Res  2018,11(9),4489-4506","journal-title":"Nano Res"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1039\/C9TB02538C","volume":"8","author":"Wang Q.","year":"2020","unstructured":"Wang Q.; He L.; Fan D.; Liang W.; Fang J.; Improving the anti-inflammatory efficacy of dexamethasone in the treatment of Rheumatoid arthritis with polymerized stealth liposomes as a delivery vehicle. J Mater Chem B Mater Biol Med  2020,8(9),1841-1851","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/1872210514666201021145233","volume":"15","author":"Kushwaha P.","year":"2021","unstructured":"Kushwaha P.; Saxena S.; Shukla B.; A recent overview on dermatological applications of liposomes. Recent Pat Nanotechnol  2021,15(4),310-321","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijpharm.2018.02.001","volume":"540","author":"Jia M.","year":"2018","unstructured":"Jia M.; Deng C.; Luo J.; A novel dexamethasone-loaded liposome alleviates Rheumatoid arthritis in rats. Int J Pharm  2018,540(1-2),57-64","journal-title":"Int J Pharm"},{"key":"ref=155","volume":"2","author":"Kataria S.","year":"2011","unstructured":"Kataria S.; Sandhu P.; Bilandi A.J.A.Y.; Akanksha M.; Kapoor B.; Stealth liposomes: A review. Int J Res Ayurveda Pharm  2011,2(5)","journal-title":"Int J Res Ayurveda Pharm"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.jddst.2019.101477","volume":"55","author":"Saraswat A.L.","year":"2020","unstructured":"Saraswat A.L.; Maher T.J.; Development and optimization of stealth liposomal system for enhanced in vitro cytotoxic effect of quercetin. J Drug Deliv Sci Technol  2020,55,101477","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/0005-2736(92)90154-E","volume":"1104","author":"Cevc G.","year":"1992","unstructured":"Cevc G.; Blume G.; Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta Biomembr  1992,1104(1),226-232","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref=158","first-page":"186","volume":"20","author":"Nayak D.","year":"2021","unstructured":"Nayak D.; Tippavajhala V.K.; A comprehensive review on preparation, evaluation and applications of deformable liposomes. Iran J Pharm Res  2021,20(1),186-205","journal-title":"Iran J Pharm Res"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/10717544.2022.2096718","volume":"29","author":"Zhao Y.P.","year":"2022","unstructured":"Zhao Y.P.; Han J.F.; Zhang F.Y.; Flexible nano-liposomes-based transdermal hydrogel for targeted delivery of dexamethasone for Rheumatoid arthritis therapy. Drug Deliv  2022,29(1),2269-2282","journal-title":"Drug Deliv"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","volume":"24","author":"Torchilin V.P.","year":"2006","unstructured":"Torchilin V.P.; Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res  2006,24(1),1-16","journal-title":"Pharm Res"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-60761-609-2_1","volume":"624","author":"Grobmyer S.R.","year":"2010","unstructured":"Grobmyer S.R.; Iwakuma N.; Sharma P.; Moudgil B.M.; What is cancer nanotechnology? Methods Mol Biol  2010,624,1-9","journal-title":"Methods Mol Biol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1039\/c3ib40165k","volume":"6","author":"Wang E.C.","year":"2014","unstructured":"Wang E.C.; Wang A.Z.; Nanoparticles and their applications in cell and molecular biology. Integr Biol  2014,6(1),9-26","journal-title":"Integr Biol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","volume":"25","author":"Zieli\u0144ska A.","year":"2020","unstructured":"Zieli\u0144ska A.; Carreir&#xF3; F.; Oliveira A.M.; Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules  2020,25(16),3731","journal-title":"Molecules"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1872210516666220131092642","volume":"17","author":"Droppa-Almeida D.","year":"2023","unstructured":"Droppa-Almeida D.; de Oliveira C.R.; Padilha F.F.; de Souza R.R.; de Albuquerque-J&#xFA;nior R.L.C.; Polymeric nanoparticles for the treatment of prostate cancer-technological prospecting and critical analysis. Recent Pat Nanotechnol  2023,17(1),8-14","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2016.03.035","volume":"230","author":"Wang Q.","year":"2016","unstructured":"Wang Q.; Jiang J.; Chen W.; Jiang H.; Zhang Z.; Sun X.; Targeted delivery of low-dose dexamethasone using PCL\u2013PEG micelles for effective treatment of Rheumatoid arthritis. J Control Release  2016,230,64-72","journal-title":"J Control Release"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1166\/jbns.2018.1525","volume":"12","author":"Sailaja A.K.","year":"2018","unstructured":"Sailaja A.K.; Lola V.S.; Formulation of mefenamic acid loaded polymeric nanoparticles for the treatment of Rheumatoid arthritis. J Bionanosci  2018,12(2),177-183","journal-title":"J Bionanosci"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1872210516666220228150624","volume":"17","author":"Qushawy M.","year":"2023","unstructured":"Qushawy M.; Alenzi A.M.; Albalawi S.A.; Alghamdi S.G.; Albalawi R.F.; Albalawi H.S.; Review on different vesicular drug delivery Systems (VDDSs) and their applications. Recent Pat Nanotechnol  2023,17(1),18-32","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"33265","DOI":"10.1021\/acsomega.1c05083","volume":"6","author":"Momekova D.B.","year":"2021","unstructured":"Momekova D.B.; Gugleva V.E.; Petrov P.D.; Nanoarchitectonics of multifunctional niosomes for advanced drug delivery. ACS Omega  2021,6(49),33265-33273","journal-title":"ACS Omega"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.jddst.2020.101581","volume":"56","author":"Bhardwaj P.","year":"2020","unstructured":"Bhardwaj P.; Tripathi P.; Gupta R.; Pandey S.; Niosomes: A review on niosomal research in the last decade. J Drug Deliv Sci Technol  2020,56,101581","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7372306","volume":"2016","author":"Ag Seleci D.","year":"2016","unstructured":"Ag Seleci D.; Seleci M.; Walter J.G.; Stahl F.; Scheper T.; Niosomes as nanoparticular drug carriers: Fundamentals and recent applications. J Nanomater  2016,2016,1-13","journal-title":"J Nanomater"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/1061186X.2021.1941060","volume":"30","author":"Akbari J.","year":"2022","unstructured":"Akbari J.; Saeedi M.; Morteza-Semnani K.; Innovative topical niosomal gel formulation containing diclofenac sodium (niofenac). J Drug Target  2022,30(1),108-117","journal-title":"J Drug Target"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/2210303108666180216151234","volume":"8","author":"Paradkar M.","year":"2018","unstructured":"Paradkar M.; Vaghela S.; Thiocolchicosideniosomal gel formulation for the pain management of Rheumatoid arthritis through topical drug delivery. Drug Deliv Lett  2018,8(2),159-168","journal-title":"Drug Deliv Lett"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1016\/S0264-410X(00)00537-5","volume":"19","author":"Conacher M.","year":"2001","unstructured":"Conacher M.; Alexander J.; Brewer J.M.; Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine  2001,19(20-22),2965-2974","journal-title":"Vaccine"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"9783","DOI":"10.2147\/IJN.S278688","volume":"15","author":"Ahmed S.","year":"2020","unstructured":"Ahmed S.; Kassem M.A.; Sayed S.; Bilosomes as promising nanovesicular carriers for improved transdermal delivery: Construction, in vitro optimization, ex vivo permeation and in vivo evaluation. Int J Nanomedicine  2020,15,9783-9798","journal-title":"Int J Nanomedicine"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/ph15091106","volume":"15","author":"Mahmoud T.M.","year":"2022","unstructured":"Mahmoud T.M.; Nafady M.M.; Farouk H.O.; Novel bile salt stabilized vesicles-mediated effective topical delivery of diclofenac sodium: A new therapeutic approach for pain and inflammation. Pharmaceuticals (Basel)  2022,15(9),1106","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.nano.2008.08.003","volume":"5","author":"Paliwal R.","year":"2009","unstructured":"Paliwal R.; Rai S.; Vaidya B.; Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine  2009,5(2),184-191","journal-title":"Nanomedicine"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/S0142-9612(01)00362-3","volume":"23","author":"Cortesi R.","year":"2002","unstructured":"Cortesi R.; Esposjto E.; Luca G.; Nastruzzi C.; Production of lipospheres as carriers for bioactive compounds. Biomaterials  2002,23(11),2283-2294","journal-title":"Biomaterials"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/02652040701799598","volume":"25","author":"Jain S.K.","year":"2008","unstructured":"Jain S.K.; Chaurasiya A.; Gupta Y.; Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul  2008,25(5),289-297","journal-title":"J Microencapsul"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/nano9091204","volume":"9","author":"Essaghraoui A.","year":"2019","unstructured":"Essaghraoui A.; Belfkira A.; Hamdaoui B.; Nunes C.; Lima S.A.C.; Reis S.; Improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles. Nanomaterials (Basel)  2019,9(9),1204","journal-title":"Nanomaterials (Basel)"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40204-015-0037-z","volume":"4","author":"Shilpi S.","year":"2015","unstructured":"Shilpi S.; Vimal V.D.; Soni V.; Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung. Prog Biomater  2015,4(1),55-63","journal-title":"Prog Biomater"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"118609","DOI":"10.1016\/j.ijpharm.2019.118609","volume":"570","author":"Valdes S.A.","year":"2019","unstructured":"Valdes S.A.; Alzhrani R.F.; Rodriguez A.; Lansakara-P DSP, Thakkar SG, Cui Z. A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2\u2032, 2\u2032-difluorodeoxycytidine with increased solubility, stability, and antitumor activity. Int J Pharm  2019,570,118609","journal-title":"Int J Pharm"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3762\/bjnano.10.174","volume":"10","author":"Esposito E.","year":"2019","unstructured":"Esposito E.; Sguizzato M.; Drechsler M.; Lipid nanostructures for antioxidant delivery: A comparative preformulation study. Beilstein J Nanotechnol  2019,10(1),1789-1801","journal-title":"Beilstein J Nanotechnol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/10717544.2018.1447050","volume":"25","author":"Zhou M.","year":"2018","unstructured":"Zhou M.; Hou J.; Zhong Z.; Hao N.; Lin Y.; Li C.; Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for Rheumatoid arthritis therapy. Drug Deliv  2018,25(1),716-722","journal-title":"Drug Deliv"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"101758","DOI":"10.1016\/j.jddst.2020.101758","volume":"57","author":"Pham C.V.","year":"2020","unstructured":"Pham C.V.; Van M.C.; Thi H.P.; Development of ibuprofen-loaded solid lipid nanoparticle-based hydrogels for enhanced in vitro dermal permeation and in vivo topical anti-inflammatory activity. J Drug Deliv Sci Technol  2020,57,101758","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/pharmaceutics12030288","volume":"12","author":"Haider M.","year":"2020","unstructured":"Haider M.; Abdin S.M.; Kamal L.; Orive G.; Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics  2020,12(3),288","journal-title":"Pharmaceutics"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","volume":"242","author":"M&#xFC;ller R.H.","year":"2002","unstructured":"M&#xFC;ller R.H.; Radtke M.; Wissing S.A.; Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm  2002,242(1-2),121-128","journal-title":"Int J Pharm"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","volume":"12","author":"Beloqui A.","year":"2016","unstructured":"Beloqui A.; Solin&#xED;s M.&#xC1;.; Rodr&#xED;guez-Gasc&#xF3;n A.; Almeida A.J.; Pr&#xE9;at V.; Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine  2016,12(1),143-161","journal-title":"Nanomedicine"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"120176","DOI":"10.1016\/j.ijpharm.2020.120176","volume":"594","author":"Sharma M.","year":"2021","unstructured":"Sharma M.; Chaudhary D.; Exploration of bromelain laden nanostructured lipid carriers: An oral platform for bromelain delivery in Rheumatoid arthritis management. Int J Pharm  2021,594,120176","journal-title":"Int J Pharm"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/17425247.2017.1372746","volume":"14","author":"Chen M.","year":"2017","unstructured":"Chen M.; Daddy J.C.K.A.; Xiao Y.; Ping Q.; Zong L.; Advanced nanomedicine for Rheumatoid arthritis treatment: Focus on active targeting. Expert Opin Drug Deliv  2017,14(10),1141-1144","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"118447","DOI":"10.1016\/j.ijpharm.2019.118447","volume":"567","author":"Zewail M.","year":"2019","unstructured":"Zewail M.; Nafee N.; Helmy M.W.; Boraie N.; Coated nanostructured lipid carriers targeting the joints \u2013 An effective and safe approach for the oral management of Rheumatoid arthritis. Int J Pharm  2019,567,118447","journal-title":"Int J Pharm"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.colsurfb.2018.06.016","volume":"170","author":"Zhang S.","year":"2018","unstructured":"Zhang S.; Wu L.; Cao J.; Effect of magnetic nanoparticles size on Rheumatoid arthritis targeting and photothermal therapy. Colloids Surf B Biointerfaces  2018,170,224-232","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/JLB.5MR0420-008RR","volume":"109","author":"Liu Y.","year":"2021","unstructured":"Liu Y.; Cao F.; Sun B.; Bellanti J.A.; Zheng S.G.; Magnetic nanoparticles: A new diagnostic and treatment platform for Rheumatoid arthritis. J Leukoc Biol  2021,109(2),415-424","journal-title":"J Leukoc Biol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"167571","DOI":"10.1016\/j.jmmm.2020.167571","volume":"523","author":"Subbiah L.","year":"2021","unstructured":"Subbiah L.; Palanisamy S.; Thamizhmurasu S.; Development of Meloxicam-chitosan magnetic nanoconjugates for targeting Rheumatoid arthritis joints: Pharmaceutical characterization and preclinical assessment on murine models. J Magn Magn Mater  2021,523,167571","journal-title":"J Magn Magn Mater"},{"key":"ref=194","author":"Santamaria P.","year":"2019","unstructured":"Santamaria P.; Nanoparticle compositions for sustained therapy.  2019"},{"key":"ref=195","author":"Bernard MA","year":"2019","unstructured":"Bernard MA; Tachado SD; Compositions and methods for treating inflammatory diseases.  2019"},{"key":"ref=196","author":"Spallitta FA","year":"2019","unstructured":"Spallitta FA; Treating autoimmune disorders with chloroquine and\/or hydroxychloroquine.  2019"},{"key":"ref=197","author":"Chen Q","year":"2020","unstructured":"Chen Q; Chen Y; Yu H; Ehrlich MG; Nanocarriers and their processing for diagnostics and therapeutics.  2020"},{"key":"ref=198","author":"Eliasof S.","year":"2020","unstructured":"Eliasof S.; Cyclodextrin-based polymers for therapeutic delivery.  2020"},{"key":"ref=199","author":"Dodd A","year":"2021","unstructured":"Dodd A; Meiser F; Norret M; Russell A; Bosch H W; Novel formulation of meloxicam.  2021"},{"key":"ref=200","author":"Stephan M.","year":"2021","unstructured":"Stephan M.; Nanoparticles for gene expression and uses thereof.  2021"},{"key":"ref=201","author":"Drennan T.","year":"2021","unstructured":"Drennan T.; Nano-penetrative cannabinoid oil blends and compositions and methods of formulation thereof.  2021"},{"key":"ref=202","author":"Dang TT","year":"2021","unstructured":"Dang TT; Nguyen TD; Inflammation-responsive anti-inflammatory hydrogels.  2021"},{"key":"ref=203","author":"Plakogiannis FM","year":"2021","unstructured":"Plakogiannis FM; Lather T; Transdermal and\/or topical pharmaceutical formulations comprising cannabidiol and\/or tetrahydrocannabinol for the treatment of chronic pain.  2021"},{"key":"ref=204","author":"Audell RA","year":"2021","unstructured":"Audell RA; Berenson RJ; Leung CYP; Microstructure systems and methods for pain treatment.  2021"},{"key":"ref=205","author":"Fraser C.","year":"2022","unstructured":"Fraser C.; Tolerogenic synthetic nanocarriers.  2022"},{"key":"ref=206","author":"Cao G","year":"2022","unstructured":"Cao G; Li YL; Mei S; Pan Y; Qian D; Zhuo J; Bipyrazole derivatives as jak inhibitors.  2022"},{"key":"ref=207","author":"Anderson DG","year":"2022","unstructured":"Anderson DG; Dorkin JR; Fenton OS; Kauffman KJ; Mcclellan RL; Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell.  2022"},{"key":"ref=208","author":"Reimann K","year":"2022","unstructured":"Reimann K; Wang R; Yu B.; Humanized anti-cd40 antibodies and uses thereof.  2022"},{"key":"ref=209","unstructured":"INCMNSZ - Rheumatoid Arthritis Cohort (IRAC)."},{"key":"ref=210","year":"2023","unstructured":"Study to assess the safety and efficacy of enbrel administered by sofusa doseconnect for Rheumatoid arthritis.  2023"},{"key":"ref=211","year":"2022","unstructured":"A phase 2 study of Hemay007 in patients with Rheumatoid arthritis.  2022"},{"key":"ref=212","year":"2019","unstructured":"Regional registry-based biobank development and pharmacogenetic analysis in Rheumatoid arthritis (RABiobank).  2019"},{"key":"ref=213","year":"2023","unstructured":"To assess the efficacy and safety of pf-06650833, pf-06651600, and tofacitinib alone and in combination in participants with active Rheumatoid arthritis with an inadequate response to methotrexate.  2023"},{"key":"ref=214","year":"2022","unstructured":"Rheumatoid arthritis MEDIcation adherence (REMEDIA).  2022"},{"key":"ref=215","year":"2019","unstructured":"Rheumatoid arthritis patients and porphyromonas gingivalis.  2019"},{"key":"ref=216","year":"2020","unstructured":"Safety, tolerability, pharmacokinetics and pharmacodynamics study\nof VAY736 in Rheumatoid arthritis patients.  2020"},{"key":"ref=217","year":"2022","unstructured":"A study of TJ003234 in Rheumatoid arthritis patients.  2022"},{"key":"ref=218","year":"2015","unstructured":"Efficacy study of dextromethorphan to treat Rheumatoid arthritis.  2015"},{"key":"ref=219","year":"2016","unstructured":"A study to assess the safety, tolerability and pharmacokinetics of\nmultiple subcutaneous injections of abbv-257 in subjects with\nRheumatoid arthritis.  2016"},{"key":"ref=220","year":"2022","unstructured":"Effect of electroacupuncture on refractory pain in juvenile Rheumatoid\narthritis: Randomized controlled trial.  2022"},{"key":"ref=221","year":"2020","unstructured":"Early phase study to assess efficacy and safety of AZD9567 versus\nprednisolone in patients with Rheumatoid arthritis.  2020"},{"key":"ref=222","year":"2020","unstructured":"The effects of hyperbaric oxygen on Rheumatoid arthritis.  2020"},{"key":"ref=223","year":"2014","unstructured":"Study in Rheumatoid arthritis for subjects who completed preceding\nstudy M13-390 with adalimumab.  2014"}],"container-title":["Recent Patents on Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872210518666230905155459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220747\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872210518666230905155459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:52:33Z","timestamp":1735069953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220747\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":223,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872210518666230905155459","relation":{},"ISSN":["1872-2105"],"issn-type":[{"value":"1872-2105","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}